GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OSTO:KARO) » Definitions » Capital Expenditure

Karo Pharma AB (OSTO:KARO) Capital Expenditure : kr-902.99 Mil (TTM As of Jun. 2022)


View and export this data going back to 1998. Start your Free Trial

What is Karo Pharma AB Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Karo Pharma AB's cash flow for capital expenditures for the three months ended in Jun. 2022 was kr0 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2022 was kr-902.99 Mil.

Karo Pharma AB Capital Expenditure Historical Data

The historical data trend for Karo Pharma AB's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Capital Expenditure Chart

Karo Pharma AB Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.80 -18.91 -34.55 -1,706.68 -900.89

Karo Pharma AB Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.40 -867.80 -9.00 -15.79 -

Karo Pharma AB Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-902.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karo Pharma AB (OSTO:KARO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OSTO:KARO) » Definitions » Capital Expenditure
Comparable Companies
LSE:HCM LSE:APH LSE:BMK LSE:INDV LSE:ANCR LSE:AGY LSE:EAH LSE:VLG LSE:CEL LSE:HELD XTER:MRK ZTS TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 VTRS SHSE:600196
Traded in Other Exchanges
N/A
Address
Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22
Website
https://www.karopharma.com
Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.